Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia

NCT02047149 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Low accrual

Conditions

Chronic Myelogenous Leukemia

Interventions

DRUG: Zileuton (Zyflo®) Dasatinib (Sprycel®)
DRUG: Dosing with Zileuton/Dasatinib in CML
DRUG: Daily dosing of Zileuton/Dasatinib
DRUG: Daily dosing with Zileuton/Dasatinib for CML

Sponsor

University of Massachusetts, Worcester

Collaborators

[object Object]